Results 241 to 250 of about 186,761 (273)

Life-Threatening Radiation Necrosis After Complete Response to Pembrolizumab in a Patient With a Metastatic Silent PIT1 Pituitary Neuroendocrine Tumor (PitNET). [PDF]

J Immunother
De Alcubierre D, Feola T, Gianno F, Verrico M, Carbonara F, Venditti E, Isidori AM, Esposito V, Minniti G, Jaffrain-Rea ML.   +9 more
europepmc   +1 more source

Timing matters: concurrent <i>vs.</i> sequential immunotherapy in combination with chemoradiation in head and neck cancer. [PDF]

Transl Cancer Res
Bachmann LM, El-Gamal D, Wise-Draper TM.
europepmc   +1 more source

Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery. [PDF]

Cancers (Basel)
Lee J, Kang B, Moon JS, Um T, Choi JE, Lee M, Chae YS, Lee SJ, Lee IH, Lee SJ, Kang SH, Koh SA, Kang SH, Park KU, Kim H, Park HY.   +15 more
europepmc   +1 more source

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer. [PDF]

ESMO Real World Data Digit Oncol
Bosveld J, Suelmann BBM, Bijlsma MJ, Franken MD, Aben KKH, ProBCI Study Group, Meijer RP, Richters A.   +7 more
europepmc   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. [PDF]

J Immunother Cancer
McKay RR, Ajmera A, Atkins MB, Barata PC, Bergerot C, Bukavina L, Choueiri TK, Desai A, Hakimi AA, Poteat S, Powles T, Rini BI, Shuch B, Signoretti S, Siva S, Xu W, Yip W, Zhang T, Pal SK.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pembrolizumab

Reactions Weekly, 2023
  +8 more sources

Pembrolizumab

Reactions Weekly
  +12 more sources

Pembrolizumab

Reactions Weekly, 2021
  +8 more sources

Pembrolizumab

Reactions Weekly, 2022
  +7 more sources

Pembrolizumab

Reactions Weekly, 2018
  +4 more sources